Smarter Analyst

NeuBase Therapeutics (NBSE) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Buy rating on NeuBase Therapeutics (NBSE) today. The company’s shares closed last Monday at $7.14.

According to TipRanks.com, Singh is a 3-star analyst with an average return of 0.9% and a 40.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on NeuBase Therapeutics is a Strong Buy with an average price target of $14.00, representing a 98.6% upside. In a report issued on March 19, Chardan Capital also reiterated a Buy rating on the stock with a $14.00 price target.

See today’s analyst top recommended stocks >>

Based on NeuBase Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $23.78 million. In comparison, last year the company had a GAAP net loss of $1.49 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.